Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89376 | 0.97 | PLA2G2A (0.66) | PLA2G2ANPC1RECQLRAB9ARXRA | |
| SCHEMBL3487150 | 0.95 | PLA2G2A (0.67) | PLA2G2ANPC1RECQLRAB9AKMT2A | |
| SCHEMBL29788135 | 0.92 | PLA2G2A (0.58) | PLA2G2ANPC1RECQLRAB9ARXRA | |
| SCHEMBL90428 | 0.92 | PLA2G2A (0.58) | PLA2G2ANPC1RECQLRAB9ARXRA | |
| SCHEMBL13461246 | 0.89 | PLA2G2A (0.73) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL10263820 | 0.87 | PLA2G2A (0.76) | PLA2G2AKMT2APLA2G4B | |
| SCHEMBL23352170 | 0.86 | PLA2G2A (0.64) | PLA2G2ANPC1RECQLRAB9AKMT2A | |
| SCHEMBL89596 | 0.85 | RAB9A (0.50) | PLA2G2ANPC1RECQLRAB9AKDM4E | |
| SCHEMBL14812062 | 0.85 | PLA2G2A (0.68) | PLA2G2ANPC1RECQLRAB9ARXRA | |
| SCHEMBL14812353 | 0.85 | PLA2G2A (0.58) | PLA2G2ANPC1RECQLRAB9ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292110-B1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-3292110-A1 | N-PIPERIDIN-4-YL DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2018-03-14 | — | — | EP | disclosed |
| US-8993757-B2 | N-piperidin-4-yl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2014-11-06 | — | — | US | disclosed |
| WO-2013041457-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | PLA2G2A 3965/4885NPC1 2702/4885RECQL 666/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | PLA2G2A 3728/4885NPC1 2676/4885RECQL 657/4885 |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | PGR, CYP19A1, BRCA1 | PLA2G2A 3596/4885NPC1 2207/4885RECQL 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.